How it unfolded
As of April 21, 2026, UnitedHealth Group (UNH) is facing a tumultuous period in the stock market. The company has experienced a staggering 22.7% drop in its stock price over the past six months, with the current price standing at $277.17. This decline has raised alarms among investors, particularly as the company prepares to announce its first-quarter earnings today.
UnitedHealth, which boasts a revenue of $447.6 billion over the past year, has seen its earnings per share (EPS) growth stall over the last five years. Wall Street analysts are projecting an EPS of $6.69 for Q1 2026, reflecting an 8% year-over-year decline. This anticipated downturn has led to heightened scrutiny regarding the company’s financial health.
In a recent development, Raymond James upgraded UNH to an “Outperform” rating, setting a price target of $330. Following this upgrade, UNH stock rose approximately 1.2%, indicating a slight recovery in investor confidence. However, the broader sentiment remains cautious, with many questioning whether now is the right time to buy.
John Ransom from Raymond James stated, “Wall Street is underestimating the company’s earnings power, particularly around cost savings.” This sentiment reflects a belief that UnitedHealth may have untapped potential, but it contrasts sharply with the current market performance and investor anxiety.
UnitedHealth’s last quarterly earnings beat was notable, with an EPS of $2.11 compared to the consensus of $2.09. Additionally, the company pays an annualized dividend of $8.84 per share, yielding around 3.2%, which could provide some solace to shareholders amid the stock’s volatility.
Institutional ownership of UnitedHealth is significant, with approximately 87.9% of the float held by institutional investors. This level of ownership underscores the importance of institutional sentiment in driving the stock’s performance. However, not all analysts are convinced of a swift recovery, as the broader Wall Street picture on UNH remains constructive yet cautious.
Details remain unconfirmed regarding the potential impact of RADV audits on UnitedHealth’s business. Additionally, a pending Ninth Circuit ruling on UnitedHealth’s preemption defense could expand legal liability if the decision goes against the company. These uncertainties add another layer of complexity to the current situation, leaving investors and analysts alike on edge as they await the earnings report.
As the market watches closely, the outcome of today’s earnings report could significantly influence UNH stock’s trajectory. Investors are left to ponder the implications of the company’s performance amidst a challenging financial landscape.